company background image
MIST logo

Milestone Pharmaceuticals NasdaqGS:MIST Stock Report

Last Price

US$2.15

Market Cap

US$145.1m

7D

9.1%

1Y

34.4%

Updated

07 Feb, 2025

Data

Company Financials +

Milestone Pharmaceuticals Inc.

NasdaqGS:MIST Stock Report

Market Cap: US$145.1m

MIST Stock Overview

A biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. More details

MIST fundamental analysis
Snowflake Score
Valuation3/6
Future Growth5/6
Past Performance0/6
Financial Health5/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

Milestone Pharmaceuticals Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Milestone Pharmaceuticals
Historical stock prices
Current Share PriceUS$2.15
52 Week HighUS$2.75
52 Week LowUS$1.12
Beta1.8
1 Month Change-2.27%
3 Month Change8.59%
1 Year Change34.38%
3 Year Change-65.54%
5 Year Change-89.75%
Change since IPO-86.01%

Recent News & Updates

Does Milestone Pharmaceuticals (NASDAQ:MIST) Have A Healthy Balance Sheet?

Nov 06
Does Milestone Pharmaceuticals (NASDAQ:MIST) Have A Healthy Balance Sheet?

Recent updates

Does Milestone Pharmaceuticals (NASDAQ:MIST) Have A Healthy Balance Sheet?

Nov 06
Does Milestone Pharmaceuticals (NASDAQ:MIST) Have A Healthy Balance Sheet?

Here's Why Shareholders Should Examine Milestone Pharmaceuticals Inc.'s (NASDAQ:MIST) CEO Compensation Package More Closely

Jun 07
Here's Why Shareholders Should Examine Milestone Pharmaceuticals Inc.'s (NASDAQ:MIST) CEO Compensation Package More Closely

Is Milestone Pharmaceuticals (NASDAQ:MIST) A Risky Investment?

Sep 13
Is Milestone Pharmaceuticals (NASDAQ:MIST) A Risky Investment?

We're Keeping An Eye On Milestone Pharmaceuticals' (NASDAQ:MIST) Cash Burn Rate

Mar 07
We're Keeping An Eye On Milestone Pharmaceuticals' (NASDAQ:MIST) Cash Burn Rate

We're Keeping An Eye On Milestone Pharmaceuticals' (NASDAQ:MIST) Cash Burn Rate

Oct 15
We're Keeping An Eye On Milestone Pharmaceuticals' (NASDAQ:MIST) Cash Burn Rate

We Think Milestone Pharmaceuticals (NASDAQ:MIST) Can Afford To Drive Business Growth

Jun 24
We Think Milestone Pharmaceuticals (NASDAQ:MIST) Can Afford To Drive Business Growth

We're Hopeful That Milestone Pharmaceuticals (NASDAQ:MIST) Will Use Its Cash Wisely

Feb 25
We're Hopeful That Milestone Pharmaceuticals (NASDAQ:MIST) Will Use Its Cash Wisely

We're Interested To See How Milestone Pharmaceuticals (NASDAQ:MIST) Uses Its Cash Hoard To Grow

Aug 25
We're Interested To See How Milestone Pharmaceuticals (NASDAQ:MIST) Uses Its Cash Hoard To Grow

Companies Like Milestone Pharmaceuticals (NASDAQ:MIST) Are In A Position To Invest In Growth

Apr 02
Companies Like Milestone Pharmaceuticals (NASDAQ:MIST) Are In A Position To Invest In Growth

What You Need To Know About Milestone Pharmaceuticals Inc.'s (NASDAQ:MIST) Investor Composition

Jan 15
What You Need To Know About Milestone Pharmaceuticals Inc.'s (NASDAQ:MIST) Investor Composition

First patient enrolled in Milestone Pharmaceuticals' late-stage study of etripamil in PSVT

Nov 18

Milestone Pharmaceuticals EPS beats by $0.09

Nov 13

Shareholder Returns

MISTUS PharmaceuticalsUS Market
7D9.1%1.2%-0.3%
1Y34.4%1.1%20.4%

Return vs Industry: MIST exceeded the US Pharmaceuticals industry which returned 1.3% over the past year.

Return vs Market: MIST exceeded the US Market which returned 22% over the past year.

Price Volatility

Is MIST's price volatile compared to industry and market?
MIST volatility
MIST Average Weekly Movement8.1%
Pharmaceuticals Industry Average Movement10.4%
Market Average Movement6.0%
10% most volatile stocks in US Market18.5%
10% least volatile stocks in US Market3.0%

Stable Share Price: MIST has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: MIST's weekly volatility (8%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
200347Joe Olivetowww.milestonepharma.com

Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company’s lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans, as well as with the Montreal Heart Institute, the WCN network, and other research centers.

Milestone Pharmaceuticals Inc. Fundamentals Summary

How do Milestone Pharmaceuticals's earnings and revenue compare to its market cap?
MIST fundamental statistics
Market capUS$145.06m
Earnings (TTM)-US$42.77m
Revenue (TTM)n/a

0.0x

P/S Ratio

-3.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
MIST income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$42.77m
Earnings-US$42.77m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.65
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio218.4%

How did MIST perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/07 05:34
End of Day Share Price 2025/02/07 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Milestone Pharmaceuticals Inc. is covered by 6 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Patrick TrucchioH.C. Wainwright & Co.
Christopher HowertonJefferies LLC
Yuchen DingJefferies LLC